Development on Cancer Therapeutic Drugs Approved by FDA in 2023
10.3971/j.issn.1000-8578.2024.24.0040
- VernacularTitle:2023年FDA批准的癌症治疗药物进展
- Author:
Qing HUANG
1
;
Chang XUE
;
Sheng HU
Author Information
1. 430079 武汉,华中科技大学同济医学院附属湖北肿瘤医院淋巴瘤内科
- Keywords:
Cancer;
Drug development;
Immunotherapy;
Targeted therapy;
Biologics
- From:
Cancer Research on Prevention and Treatment
2024;51(7):542-545
- CountryChina
- Language:Chinese
-
Abstract:
Since the beginning of the 21st century,the field of cancer drug development has undergone significant changes.Kinase inhibitors are the product category with the highest number of approved drugs and indications.However,despite checkpoint inhibitors being only introduced to the market since 2011,they have become the second most approved product categories.In the year of 2023,the FDA's Center for Drug Evaluation and Research(CDER)has approved 13 new cancer therapeutic drugs.In the past five years,a slight increase in drug approvals targeting biomarker-defined populations as well as emerging approvals that are agnostic to tumor anatomy has been recorded.Currently,new treatment approaches and technologies,such as the development of Artificial Intelligence(AI),have increasingly profound progress on cancer drug development.
